US OptionsDetailed Quotes

CCCC250117P1000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayTrading Jan 22 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

Comments

    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
    Tuesday, 14th January at 7:00 am
    Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma
    CFT1946 Phase 1 Trial Continues to Progress in BRAF V600X Solid Tumors With Monoth...
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
    Positive
    36% overall response rate and 45% clinical benefit rate achieved in MM at highest dose level
    38% overall response rate in NHL across all subtypes
    44% overall response rate in PTCL specifically
    No treatment emergent adverse events leading to dose reduction
    Well-tolerated safety profile...
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
    C4 Therapeutics (CCCC) presented Phase 1 trial data for cemsidomide at the ASH Annual Meeting, showing promising results in both multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). In MM, cemsidomide with dexamethasone achieved a 36% overall response rate and 45% clinical b...
    $C4 Therapeutics (CCCC.US)$ In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels
    Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Le...
Read more